Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in shares of Catalent (NYSE:CTLT) during the 4th quarter, HoldingsChannel reports. The fund purchased 5,900 shares of the company’s stock, valued at approximately $242,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. raised its position in Catalent by 25.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock worth $41,773,000 after acquiring an additional 210,296 shares in the last quarter. American International Group Inc. raised its position in Catalent by 2.6% during the fourth quarter. American International Group Inc. now owns 362,257 shares of the company’s stock worth $14,882,000 after acquiring an additional 9,152 shares in the last quarter. Eagle Boston Investment Management Inc. raised its position in Catalent by 40.0% during the fourth quarter. Eagle Boston Investment Management Inc. now owns 7,349 shares of the company’s stock worth $306,000 after acquiring an additional 2,101 shares in the last quarter. Legal & General Group Plc raised its position in Catalent by 25.1% during the third quarter. Legal & General Group Plc now owns 133,466 shares of the company’s stock worth $5,323,000 after acquiring an additional 26,756 shares in the last quarter. Finally, Pier Capital LLC bought a new stake in Catalent during the third quarter worth $5,545,000. 99.89% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the transaction, the senior vice president now directly owns 46,986 shares of the company’s stock, valued at $1,964,014.80. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.70% of the stock is currently owned by company insiders.
NYSE:CTLT opened at $41.06 on Friday. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87. The stock has a market cap of $5,474.07, a P/E ratio of 25.66, a price-to-earnings-growth ratio of 2.37 and a beta of 1.54. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The business had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. During the same period last year, the firm earned $0.27 earnings per share. Catalent’s revenue for the quarter was up 25.3% compared to the same quarter last year. equities research analysts anticipate that Catalent will post 1.52 earnings per share for the current year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.